1921
Live-attenuated dengue vaccine development
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Serial passage at low dilution of seven different wild-type dengue (DEN) viruses into primary dog kidney (PDK) cell cultures placed selective pressure that resulted in the following changes from parental phenotype: smaller plaques in LLC-MK2 cells, absent plaque formation in green monkey kidney cells, lack of a cytopathic effect in LLC-MK2 cells, shut-off of virus replication at high temperatures (temperature sensitivity), reduced virulence for rhesus monkeys manifested by reduced or absent viremia and/or absence of a secondary-type antibody response following homotypic challenge, and progressive increase in the mean day of death following intracerebral inoculation of sucking mice. Two DEN-1 strains showed most of these changes by the 15th PDK passage. Only one of two DEN-2 strains studied was carried to the 50th PDK passage at the University of Hawaii. For the latter strain, both the temperature of viral replicative shutoff and mouse neurovirulence were reduced. Three DEN-4 strains showed similar late-passage biologic marker changes. The observations made, although not exhaustive, provide laboratory correlates for virus strains that have shown reduced virulence but retained immunogenicity in humans. Candidate human vaccines have been prepared from five of the studied strains: DEN-1 (16007) at PDK 13, DEN-2 (16681 and S-16803) at PDK 50 or above, and DEN-4 (1036 and 341750) at PDK 48 and 20, respectively.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2003.69.6_suppl.0690005
2003-12-01
2017-11-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/69/6_suppl/0690005.html?itemId=/content/journals/10.4269/ajtmh.2003.69.6_suppl.0690005&mimeType=html&fmt=ahah

References

  1. Halstead SB, Diwan AR, Marchette N.J, Palumbo NE, Srisukonth L, 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned viruses at different passage levels. Am J Trop Med Hyg 33: 654–665.
  2. Halstead SB, Marchette NJ, Diwan AR, Palumbo NE, Putvatana R, 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. II. Attributes of virus cloned at different dog kidney passage levels. Am J Trop Med Hyg 33: 666–671.
  3. Halstead SB, Marchette NJ, Diwan AR, Palumbo NE, Putvatana R, Larsen K, 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. III. Reversion to virulence by passage of cloned virus in fetal rhesus lung cells. Am J Trop Med Hyg 33: 672–678.
  4. Halstead SB, Eckels KH, Putvatana R, Larsen LK, Marchette NJ, 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells. Am J Trop Med Hyg 33: 679–683.
  5. Eckels KH, Scott R McN, Bancroft WH, Brown J, Dubois DR, Summers PI, Russell PK, Halstead SB, 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg 33: 684–689.
  6. Marchette NJ, Dubois DR, Larsen LK, Summers PL, Kraiselburd EG, Gubler DJ, Eckels KH, 1990. Preparation of an attenutated dengue 4 (341750 Carib) virus vaccine. I Pre-clinical studies. Am J Trop Med Hyg 43: 212–218.
  7. Bhamarapravati N, Yoksan S, 1997. Live-attenuated tetravalent dengue vaccine. Gubler DJ, Kuno G, eds. Dengue and Dengue Hemorrhagic Fever. Wallingford, United Kingdom: CAB International, 367–377.
  8. Bhamarapravati N, Yoksan S, Chayanyayothin T, Augsubphakorn S, Bunyaratvej A, 1987. Immunization with a live-attenuated dengue-2 virus candidate vaccine (16681-PDK-53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 65: 189–195.
  9. Augsubhakorn S, Yoksan S, Bhamarapravati N, Moe JB, Marchette NJ, Pradermwong A, Sahaphong S, 1988. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys. Trans R Soc Trop Med Hyg 82: 746–749.
  10. Bhamarapravati N, Yoksan S, 1989. Study of bivalent dengue vaccine in volunteers (letter). Lancet 1: 1077.
  11. Augsubhakorn S, Yoksan S, Pradermwong A, Nitatpattana N, Sahaphong S, Bhamarapravati N, 1994. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis. Southeast Asian J Trop Med Public Health 25: 554–559.
  12. Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, Rice RM, Bhamarapravati N, 1996. Testing of a dengue 2 live-attenuated vaccine (strain 16681PDK 53) in ten American volunteers. Vaccine 14: 329–336.
  13. Hoke CH Jr, Malinwski FJ, Eckels KH, Scott RMcN, Dubois DDR, Summers PL, Simms T, Burrous J, Hasty S, Bancroft WH, 1990. Preparation of an attenuated dengue 4 (341750 Carib) vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg 43: 219–226.
  14. Halstead SB, Char DFB, Diwan AR, 1970. Evaluation of three rubella vaccines in adult women. JAMA 211: 911–916.
  15. Hammon W McD, Rudnick A, Sather GE, 1960. Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 131: 1102–1103.
  16. Henchal EA, Repik PM, McCown JM, Brandt WE, 1986. Identification of an antigenic and genetic variant of dengue-4 virus from the Caribbean. Am J Trop Med Hyg 35: 393–400.
  17. Halstead SB, Udomsakdi S, Simasthien P, Singharaj P, Sukhavachana P, Nisalak A, 1970. Observations related to pathogenesis of dengue hemorrhagic fever. I. Experience with classification of dengue viruses. Yale J Biol Med 42: 261–275.
  18. Halstead SB, Simasthien P, 1970. Observations related to pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J Biol Med 42: 276–292.
  19. Clarke DH, Casals J, 1958. Techniques for hemagglutination and hemagglutination- inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7: 561–573.
  20. Barrett AD, Monath TP, Cropp CB, Adkins JA, Ledger TN, Gould EA, Schlesinger JJ, Kinney RM, Trent DW, 1990. Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol 71: 2301–2306.
  21. Dunster LM, Wang H, Ryman KD, Miller BR, Watowich SJ, Minor PD, Barrett AD, 1999. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology 261: 309–318.
  22. Nityaphan S, Grant JA, Chang GJ, Trent DW, 1990. Nucleotide sequence of the virulent SA14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA14-14-2. Virology 177: 541–552.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2003.69.6_suppl.0690005
Loading
/content/journals/10.4269/ajtmh.2003.69.6_suppl.0690005
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error